Thuy Vu
Family · Dallas, TXNPI 1801191747
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,060 of the $5,026 with a category attached, or 60.9%. Gilead accounts for 74.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $3,474 and has fallen 85.4% since, to $507 in 2025. Among family clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 75 payments — averaging $67.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- AbbVie$434
- Intercept Pharmaceuticals, Inc.$241
- Orphalan Inc$197
- Dermavant Sciences, Inc.$135
- Sun Pharmaceutical Industries Inc.$111
- plus $179 from 3 others
What the payments were for
- Consulting fees$3,06061%
- Travel & lodging$501%
- Food & beverage$1,84637%
- Education$701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 16 | $3,729 |
| AbbVie | 16 | $434 |
| Intercept Pharmaceuticals, Inc. | 2 | $241 |
| Orphalan Inc | 3 | $197 |
| Dermavant Sciences, Inc. | 24 | $135 |
| Sun Pharmaceutical Industries Inc. | 6 | $111 |
| Regeneron Healthcare Solutions, Inc. | 2 | $90 |
| Organon | 5 | $72 |
| Pfizer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,026 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tenofovir Disoproxil Fumarate | 15 | $7,474 |
| Carvedilol | 30 | $137 |
| Nortriptyline Hcl | 11 | $45 |
Paid to pharmacies, not to this prescriber.
Other family in Dallas
- David WeirDallas$959K
- Sie ThomasDallas$197K
- Marcia HarrisDallas$156K
- Miles HortonDallas$72K
- Natasha SimmonsDallas$38K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.